Streetbeat News

YPHDF

Ypsomed Holding AG

CEO

Simon Michel

Industry

Surgical and Medical Instrument Manufacturing

Open

362.00

Mkt cap

6.1B

Volume

High

445.74

P/E Ratio

68.47

52-wk high

496.25

Low

362.00

Div yield

0.00

52-wk low

261.00

Swiss medical technology company Ypsomed (OTC:YPHDF) has announced a long-term supply deal with Novo Nordisk A/S (NYSE:NVO) for autoinjectors. The autoinjectors will be used for various drugs currently undergoing clinical trials. Ypsomed will expand its manufacturing capacities over the coming years, with Novo Nordisk contributing a significant part of the investment for the additional production infrastructure. The first step with significant capacity for manufacturing YpsoMate autoinjectors will be available for Novo Nordisk in 2025.

Portfolio Pulse from Vandana Singh

September 20, 2023 | 2:32 pm

Ypsomed has signed a long-term supply agreement with Novo Nordisk for large quantities of autoinjectors. The autoinjectors will be used for self-treatment in various metabolic indications. Novo Nordisk is contributing a significant part of the investment for the new additional production infrastructure. The first step with significant capacity for manufacturing YpsoMate autoinjectors will be available for Novo Nordisk in 2025.

Portfolio Pulse from Charles Gross

September 20, 2023 | 8:47 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.